PT-141 (Bremelanotide): Complete Guide to Benefits, Dosing, and Research (2026)

PT-141, the peptide better known by its generic name bremelanotide, occupies a genuinely unique position in the pharmacology of sexual dysfunction. Unlike every other drug in this space — Viagra, Cialis, flibanserin — it does not work on the genitals. It works on the brain. Specifically, it targets a network of melanocortin receptors in the hypothalamus and limbic system that govern sexual desire and motivation.

This central mechanism makes PT-141 relevant to a much wider range of patients than conventional treatments: men who don't respond to PDE5 inhibitors, women with hypoactive sexual desire disorder, and anyone whose sexual dysfunction is rooted in low libido rather than mechanical vascular insufficiency. It is also the only FDA-approved peptide in the sexual health space, sold under the brand name Vyleesi.

This guide covers everything clinically relevant about PT-141: how it works, what the evidence actually shows, dosing protocols, side effects, and how to access it legally in 2026.

What Is PT-141?

PT-141 is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide in the melanocortin system. It was developed by Palatin Technologies initially as a treatment for erectile dysfunction via intranasal delivery in the early 2000s, before pivoting to a subcutaneous injection formulation for female hypoactive sexual desire disorder (HSDD).

In June 2019, the FDA approved bremelanotide 1.75 mg subcutaneous injection (brand name: Vyleesi) for premenopausal women with acquired, generalized HSDD — making it only the second FDA-approved drug for female sexual dysfunction, after flibanserin (Addyi). Cosette Pharmaceuticals acquired the rights to Vyleesi from Palatin Technologies in late 2023 and currently markets the drug.

Mechanism of Action: Why PT-141 Is Different

To understand why PT-141 matters, it helps to understand what it does not do. PDE5 inhibitors like sildenafil and tadalafil work by relaxing smooth muscle in penile blood vessels, increasing blood flow in response to sexual stimulation. They do nothing for desire — they require arousal to already be present. If the problem is that a person doesn't want sex, Viagra won't help.

PT-141 works upstream of all of that. As a melanocortin receptor agonist, it binds primarily to MC3R and MC4R receptors in the paraventricular nucleus of the hypothalamus and connected limbic regions. MC4R activation triggers dopamine release in the medial preoptic area — a region integral to sexual motivation and desire.

This means PT-141 can initiate the desire for sexual activity from a neurological level, not just facilitate a physical response to existing arousal. It is the only drug that works this way in clinical use today.

PT-141 is also active at MC1R and MC5R, though not MC2R (the ACTH/cortisol receptor). MC1R activation is responsible for one of PT-141's notable side effects: skin hyperpigmentation with prolonged use.

Clinical Evidence

Women: Phase 3 RECONNECT Trials

The pivotal evidence supporting FDA approval came from two identical Phase 3 randomized controlled trials — the RECONNECT studies — enrolling 1,247 premenopausal women with acquired, generalized HSDD over 24 weeks.

Key findings:

• Approximately 25% of bremelanotide-treated women showed a clinically meaningful increase in sexual desire (vs. ~17% on placebo)
• Approximately 35% showed a clinically meaningful reduction in distress related to low desire (vs. ~31% on placebo)
• Results were statistically significant, though the effect sizes were modest in absolute terms

A 52-week open-label extension study confirmed both the sustained efficacy and the safety profile over longer-term use.

Men: Phase 2 Evidence

While no FDA-approved indication exists for men, multiple Phase 2 trials have demonstrated efficacy in male sexual dysfunction:

• A large 2007 AUA-presented trial of intranasal PT-141 in 726 men with erectile dysfunction showed significant improvements in erectile response
• A placebo-controlled trial in 342 men with sildenafil-failure ED: approximately 33.5% of PT-141 users achieved erections sufficient for intercourse vs. 8.5% on placebo
• A Phase 2B trial in diabetic men with ED reported statistically significant improvements in IIEF scores
• Co-administration of PT-141 with low-dose sildenafil produced significantly stronger erectile responses than sildenafil alone, suggesting synergy between the central and peripheral pathways

Palatin Technologies has ongoing work evaluating a fixed-dose combination of bremelanotide with a PDE5 inhibitor in a single subcutaneous injection specifically for men who are PDE5-inhibitor non-responders.

Dosing Protocols

FDA-Approved Dosing (Vyleesi)

• Dose: 1.75 mg subcutaneous injection via autoinjector pen
• Location: Abdomen or thigh
• Timing: Approximately 45 minutes before anticipated sexual activity
• Frequency: Maximum 1 dose per 24 hours; maximum 8 doses per month

The monthly dose cap exists because exceeding 8 doses per month meaningfully raises the risk of skin hyperpigmentation, a potentially permanent side effect driven by MC1R activation.

Compounded Formulations (Off-Label)

• Starting dose: 250–500 mcg subcutaneous, to assess tolerability (primarily nausea)
• Therapeutic range: 500 mcg to 2 mg subcutaneous
• Onset: 30–60 minutes
• Duration: 6–12 hours
• Nasal spray (compounded): Approximately 50–60% bioavailability vs. subcutaneous; higher doses required for equivalent effect

Some men's health clinics use combination compounded formulations pairing PT-141 with oxytocin, tadalafil, or both in a single preparation, though controlled trial data on these combinations remains limited.

A note on nasal spray history: The intranasal route was PT-141's original delivery method in early clinical trials. The FDA halted intranasal development in 2007 due to blood pressure variability from inconsistent nasal absorption. Palatin discontinued the nasal formulation and all subsequent Phase 3 development used subcutaneous injection. Compounded nasal sprays remain available today, but absorption consistency is a clinical concern.

Side Effects and Safety Profile

Common Side Effects

• Nausea (~40%): The most frequent adverse effect; most common with the first injection and often improves with subsequent doses. Pre-medicating with anti-nausea medication and remaining horizontal for 30–60 minutes after dosing significantly reduces severity.
• Flushing/hot flashes (~20%)
• Injection site reactions (~13%)
• Headache (~11%)

Cardiovascular Effects

PT-141 causes a transient blood pressure increase of approximately +6 mmHg systolic and +3 mmHg diastolic, peaking within 4 hours of administration and returning to baseline by 8–10 hours. For most healthy individuals this is clinically insignificant, but it is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

Hyperpigmentation

Focal skin discoloration — most commonly affecting the face, gums, and breasts — can develop with cumulative use exceeding 8 doses per month. Driven by MC1R activation, this effect may be permanent. It is the primary reason the FDA's approved labeling imposes a monthly dose cap.

Contraindications

• Uncontrolled hypertension
• Known cardiovascular disease
• Concurrent nitrate use
• Pregnancy

PT-141 vs. Other Sexual Dysfunction Treatments

PT-141 and PDE5 inhibitors are not truly competing drugs — they target entirely different parts of the sexual response system. PDE5 inhibitors increase blood flow in response to existing arousal; PT-141 initiates desire at the neurological level. These approaches are mechanistically complementary, which is why combination use often produces additive benefit rather than redundancy.

Compared to flibanserin (Addyi) — the other FDA-approved option for female HSDD — PT-141 offers on-demand dosing rather than requiring daily chronic administration, and avoids flibanserin's serious alcohol interaction risk. However, flibanserin is oral while PT-141 requires subcutaneous injection.

For men who have failed PDE5 inhibitors entirely, PT-141 represents one of the only evidence-backed alternatives, operating through a completely separate neurological pathway.

Legal Status and Compounding Pharmacy Access

United States

Vyleesi (1.75 mg autoinjector) is an FDA-approved prescription drug available with a valid prescription through specialty pharmacies and major telehealth platforms. Prescriptions grew approximately 20% year-over-year in 2025, driven largely by telemedicine access.

Compounded bremelanotide is available through 503A compounding pharmacies with a valid physician prescription, enabling off-label use in men, alternative dosage forms (including nasal spray and lower-concentration injections), combination formulations, and dose titration. Because bremelanotide is an FDA-approved drug — unlike unapproved research peptides such as BPC-157 or TB-500 — it has significantly stronger legal standing for compounding under 503A patient-specific rules, even amid the broader FDA scrutiny of compounded peptides during 2024–2026.

International

Bremelanotide is not approved in the EU or most international markets as of 2026. It is available through some private clinics, but the regulatory landscape outside the US is substantially less clear.

2025–2026 Research Updates

• Palatin Phase 2 (men, PDE5 non-responders): An ongoing open-label trial evaluates a fixed-dose bremelanotide + PDE5 inhibitor combination injection for men who fail standard ED treatment; Phase 3 is planned if results are positive
• Telehealth-driven growth: Vyleesi prescriptions grew ~20% year-over-year in 2025 through telemedicine platforms
• Melanocortin system research: The related approved drug setmelanotide (Imcivree), which targets MC4R for rare obesity syndromes, continues to advance scientific understanding of the broader melanocortin pathway that PT-141 also activates

Who Is PT-141 Most Appropriate For?

• Premenopausal women with acquired, generalized HSDD (the approved indication with Phase 3 data)
• Men with psychogenic or mixed-etiology erectile dysfunction
• Men who fail PDE5 inhibitors (different mechanism; Phase 2 evidence in sildenafil non-responders)
• Patients of either sex with libido deficits not adequately addressed by hormonal therapies
• Patients seeking an on-demand treatment option rather than chronic daily dosing

Conclusion

PT-141 is not a replacement for Viagra. It is something more clinically interesting: a pharmacological tool that addresses the neurological side of sexual dysfunction — desire and arousal at the brain level — that every other approved drug in this space currently ignores.

Its FDA approval for women with HSDD provides a legitimate clinical and regulatory foundation that most research peptides lack. Its off-label use in men, supported by multiple Phase 2 trials including in sildenafil non-responders, makes it one of the more evidence-backed options in peptide medicine. And its unique central mechanism — initiating sexual desire neurologically rather than facilitating a peripheral vascular response — means it fills a gap no other approved drug currently occupies.

For patients who've tried and failed PDE5 inhibitors, or who find that the issue isn't blood flow but desire, PT-141 deserves serious clinical consideration.

This article is for educational and informational purposes only. PT-141 (bremelanotide) is a prescription drug. Consult a qualified healthcare provider before starting any peptide or hormone therapy.